Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Alessa Therapeutics General Information
Alessa has initiated first-in-human Phase I studies of its Enolen® implant for localized sustained delivery of enzalutamide in prostate cancer patients. Early feasibility testing with the Biolen® system has been completed. The company’s approach aims to deliver anti-androgen therapy directly to the prostate, potentially reducing systemic side effects seen with current therapies. Initial data from ongoing trials are expected soon.[3][5][10]
Contact Information
Primary Industry
Biotech
Corporate Office
San Carlos, California
United States
United States
Drug Pipeline
apalutamide
Phase 1Key Partnerships
National Cancer Institute / NIH – collaboration on clinical studies including first-in-human trial of Enolen and Biolen systems[5][9], Johnson & Johnson Innovation – JJDC, Inc. – investor and board representation through venture arm participation[3]
Alessa Therapeutics Funding
No funding data available
To view Alessa Therapeutics's complete valuation and funding history, request access »